Stobadine inhibits lysosomal enzyme release in vivo and in vitro.
This study investigated the ability of stobadine, an effective cardioprotective drug with antiarrhythmic, antihypoxic and oxygen free radical scavenging properties, to protect cells against cyclophosphamide-induced toxic and cytotoxic damage in vivo and in vitro. Cyclophosphamide-induced toxic damage in female ICR mice was accompanied by marked increase in the activity of lysosomal enzymes in the spleen and kidney. Administration of stobadine prior to cyclophosphamide inhibited these biochemical changes. The in vivo protective effect of stobadine was comparable with its in vitro effect established in HeLa cells.
Navarová
J
J
Institute of Experimental Pharmacology SASc, Bratislava, Slovak Republic.
Macicková
T
T
Horáková
K
K
Urbancíková
M
M
D000118:Acetylglucosaminidase / Q000378:metabolism; D000135:Acid Phosphatase / Q000378:metabolism; D000477:Alkylating Agents / Q000037:antagonists & inhibitors / Q000633:toxicity; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D002243:Carbolines / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors / Q000633:toxicity; D003864:Depression, Chemical; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008247:Lysosomes / Q000187:drug effects / Q000201:enzymology*; D051379:Mice; D008813:Mice, Inbred ICR; D013154:Spleen / Q000187:drug effects / Q000201:enzymology
D000477:Alkylating Agents; D000975:Antioxidants; D002243:Carbolines; D016166:Free Radical Scavengers; D003520:Cyclophosphamide; D000135:Acid Phosphatase; D000118:Acetylglucosaminidase; C100106:dicarbine